galantamine hydrobromide

Also found in: Dictionary.

galantamine hydrobromide

Razadyne, Razadyne ER, Reminyl (UK), Reminyl XL (CA) (UK)

Pharmacologic class: Cholinesterase inhibitor

Therapeutic class: Anti-Alzheimer's agent

Pregnancy risk category B


Unclear. May reversibly inhibit acetylcholinesterase, increasing concentration of acetylcholine (necessary for nerve impulse transmission) in brain synapses.


Capsules (extended-release): 8 mg, 16 mg, 24 mg

Oral solution: 4 mg/ml

Tablets: 4 mg, 8 mg, 12 mg

Indications and dosages

Mild to moderate dementia of Alzheimer's disease

Adults: Initially, 4 mg P.O. b.i.d. If patient tolerates dosage well after at least 4 weeks of therapy, increase to 8 mg P.O. b.i.d. May increase to 12 mg P.O. b.i.d. after at least 4 weeks at previous dosage. Recommended range is 16 to 24 mg daily in two divided doses. Or initially, 8 mg P.O. daily (Razadyne ER). If patient tolerates dosage after at least 4 weeks, increase to 16 mg P.O. daily. Further increase to 24 mg P.O. daily should be attempted after minimum of 4 weeks at 16 mg/day.

Dosage adjustment

• Moderate hepatic or renal impairment

Off-label uses

• Vascular dementia


• Hypersensitivity to drug

• Severe hepatic or renal impairment

• Pregnancy or breastfeeding

• Children


Use cautiously in:

• asthma, chronic obstructive pulmonary disease, GI bleeding, moderate hepatic or renal impairment, Parkinson's disease, seizures.


• Before giving, make sure patient is well hydrated, to minimize GI upset.

• Give with morning and evening meals.

• Give with antiemetics as needed.

• Use pipette to add oral solution to beverage; have patient drink it right away.

Adverse reactions

CNS: depression, dizziness, headache, tremor, insomnia, drowsiness, fatigue, syncope

CV: bradycardia

EENT: rhinitis

GI: nausea, vomiting, diarrhea, abdominal pain, dyspepsia, anorexia

GU: urinary tract infection, hematuria

Hematologic: anemia

Other: weight loss


Drug-drug Anticholinergics: antagonism of anticholinergic activity

Cholinergics: synergistic effects

Cimetidine, erythromycin, ketoconazole, paroxetine: increased galantamine bioavailability

Patient monitoring

• Assess fluid intake and output to ensure adequate hydration, which helps reduce GI upset.

• Monitor cognitive status.

• Evaluate patient for cardiac conduction abnormalities. Assess pulse regularly for bradycardia.

• Observe for bleeding tendencies.

Assess for depression and suicidal ideation.

Patient teaching

• Instruct caregiver in proper technique for using oral pipette.

• Teach caregiver how to measure patient's pulse. Tell him to report slow pulse right away.

• Recommend frequent, small servings of healthy food and adequate fluids to minimize GI upset.

Tell patient or caregiver to watch for and report signs and symptoms of depression.

• Advise patient or caregiver to establish effective bedtime routine.

• Caution caregiver to prevent patient from performing hazardous activities until adverse reactions are known.

• As appropriate, review all other significant adverse reactions and interactions, especially those related to the drugs mentioned above.

McGraw-Hill Nurse's Drug Handbook, 7th Ed. Copyright © 2013 by The McGraw-Hill Companies, Inc. All rights reserved
Mentioned in ?
References in periodicals archive ?
Galantamine hydrobromide was used as inhibitor of the enzymes.
Canadian health authorities have issued a public advisory concerning the safety of galantamine hydrobromide as a treatment for mild cognitive impairment--an off-label use.
* The Food and Drug Administration recently approved Reminyl (galantamine hydrobromide), a new treatment for mild to moderate Alzheimer's disease.
The company's abbreviated new drug application was approved for galantamine hydrobromide in 8-, 16- and 24-mg forms.